Investor Home
 | 2011 Annual Report |
| Stock Quote |
 |
| Corporate Profile |
|
| Recent News | More >> |
| MediciNova Reports First Quarter 2013 Results - 05/08/13 |
| SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for... More >> |
|
| MediciNova Reports Fourth Quarter and Full Year 2012 Results - 03/28/13 |
| SAN DIEGO , March 28, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results... More >> |
|
| MediciNova Announces MN-166 (ibudilast) Opioid Withdrawal and Analgesia Data Presentation at the American Academy of Neurology Annual Meeting - 03/20/13 |
| SAN DIEGO, March 20, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced ... More >> |
|
| FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Methamphetamine Dependence - 02/25/13 |
| SAN DIEGO, Feb. 25, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced t... More >> |
|
| MediciNova Provides Development Update - 01/03/13 |
| Company Finalizing Development Plans for MN-221 While Enhancing MN-166 Program SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq... More >> |
|
| MediciNova Receives Notice of Patent Allowance for Method of Treating Acute Exacerbations of Asthma - 12/09/12 |
| SAN DIEGO, Dec. 9, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced that it ... More >> |
|
| MediciNova Announces Initiation of a Clinical Trial of MN-166 in Opioid Abusers With Columbia University and the New York State Psychiatric Institute - 11/20/12 |
| Phase 2a Trial With Ibudilast Funded by the National Institute of Drug Abuse (NIDA) SAN DIEGO, Nov. 20, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of t... More >> |
|
| MediciNova Extends MN-166 Patent Position in Europe - 11/18/12 |
| Notices of Allowance for Ibudilast Use in Drug Addiction and in Acute Pain With Opioids SAN DIEGO, Nov 18, 2012 (GLOBE NEWSWIRE via COMTEX) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the ... More >> |
|
| MediciNova to Present at the Fourth World Congress of Emergency Medicine - 11/14/12 |
| Outcomes of the Phase 2 Trial of MN-221 in Acute Exacerbation of Asthma SAN DIEGO, Nov. 14, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Sec... More >> |
|
| MediciNova Announces Publication of MN-221 Clinical Results in Journal of Asthma - 11/12/12 |
| SAN DIEGO, Nov. 12, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the publication of ... More >> |
|
|
| Upcoming Events | More >> |
| There are currently no events scheduled. |
|
| What's New |
| There are currently no items available. |
|
Receive E-mail Alerts |
| Sign up to receive e-mail alerts whenever Medicinova Inc posts new information to the site. Just enter your e-mail address and click Submit. |
|
 Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
Investor Tools
 | Print Page |
 | E-mail Page |
 | RSS Feeds |
 | E-mail Alerts |
 | IR Contacts |
Stock Information
|
MNOV (Common)
$3.54 + 0.15 | 05/17/13 4:00 p.m. ET |
|
